Herein, we have reviewed and analysed recent literature, published in 2013 and early 2014,
in the context of pre-existing data. Considered target therapies were tyrosine kinase …

The discovery of oncogenic driver mutations and the subsequent developments in targeted
therapies have led to improved outcomes for subsets of lung cancer patients. The …

The advent of widespread cancer genome sequencing has accelerated our understanding
of the molecular aberrations underlying malignant disease at an unprecedented rate …

The use of molecularly targeted agents has dramatically improved the prognosis of defined
subsets of patients with non-small-cell lung cancer harboring somatically activated …

The recent discovery of relevant biomarkers has reshaped our approach to therapy selection
for patients with non-small cell lung cancer. The unprecedented outcomes demonstrated …

Introduction: The discovery of molecular biomarkers and the advent of targeted therapies
have led to a radical change in the treatment of several tumors, including NSCLC. In the last …

The programmed death 1 (PD-1) pathway is an immune checkpoint that has been implicated
in tumoral immune escape, and has emerged as a major focus of immunotherapy in non …

Opinion Statement ALK rearrangements are present in 3–5% of patients with non-small cell
lung cancer (NSCLC) and after epidermal growth factor receptor (EGFR) mutations …

Management paradigms for metastatic non–small cell lung cancer (mNSCLC) are evolving.
Locally ablative therapies are now being increasingly integrated into combined-modality …

Crizotinib was the first clinically available anaplastic lymphoma kinase (ALK) inhibitor,
showing remarkable activity against ALK-rearranged non-small-cell lung cancer (NSCLC) …